Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
MMs playing this like a fiddle...back to .45...🥳
SGMO...45s hitting here in the P/M...Off the .33 dip...🥳
While it wasn't many shares, it did hit .45 AH's, with a tiny hit @ .4519.
Finished the AH's @ .43 and on the move up at this moment.
Nice close ...just need it to Break/Hold .42...🥳
SGMO: .40 @ close, now .42 AH's.
SGMO...3912...HOD...Nice candle forming here...🥳Like to see a Break/Hold of .43 range for now...
SGMO: Very good sign, breaking the morning high. (.3889) Especially after all the whacking, following that morning high.😜
SGMO...37s clearing here...🥳
georgie18
Member Level
Re: None
Wednesday, July 10, 2024 9:24:02 AM
Post#
381804
of 381814
SGMO...33...Looks Like a Reversal setting up here... https://schrts.co/fxvIUFMa ...Adding here...🥳
SGMO...33...Looks Like a Reversal setting up here... https://schrts.co/fxvIUFMa ...Adding here...🥳
It always sucks until it doesn't...🥳lets see where she lands...
The PPS sucks for now, but I'm taking chance that some sort of deal, that provides revenue will be reached this quarter. Kind of a All or Nothing type of thing.
I haven't added in weeks, but am bidding in a couple of spots below 30.
Good Luck if you are still holding.
https://www.nasdaq.com/market-activity/stocks/sgmo/analyst-research
Thanks ...market closed yesterday ...lets see what today brings...🥳
SGMO: Looks like we're waiting on a Boom or Bust, no shares traded so far.
Estimated date of Ph. 3 Primary Completion was 06-17-24 and after that drop in PPS recently, which looked like a Short Cover Smackdown, I'm hoping for a move North at any time???
(Concerning the possible Smackdown. That could explain why we have no volume today. Shorts are out? IB's Borrow Rate is .8% today.)
https://clinicaltrials.gov/study/NCT04370054
Also has a lot of room to go up.
For anyone who can read ahead, yesterday's filing was not a shock. Look at the chart below and it will show the market knew it was coming.
But the news that came with it, about future developments actually sent the pps higher today than all week.
Some folks can't figure out why their trades fail. It's timing.
https://www.barchart.com/stocks/quotes/SGMO/interactive-chart
Sangamo Therapeutics traded @ ( $0.2911 ) on ( November 13, 2023 ), this has a massive amount of room to go down ⏬ 🍂🍁 to that level again, especially with the earnings report that came out yesterday ( May 9, 2024 )
Sangamo Therapeutics Flawless Balance ⚖️ Sheet And Extremely Undervalued... Fair Value ( $30.70 ) A Share
Sangamo Therapeutics traded @ ( $0.2911 ) on ( November 13, 2023 ), this has a massive amount of room to go down ⏬ 🍂🍁 to that level again, especially with the earnings report coming out on Monday ( April 29, 2024 )
It would seem so but as each do goes on the faith in sandy to get anything down keeps going down. Really hard to have any faith in that liar.
They should not get a darn penny sandy drove the stock right back into the ground after the run to 1.40. He still cannot get a Farby deal done which is beyond absurd.
So they have chosen to not communicate with their customers as to the issue(s) and timing of a return? If they are closing down the website, then should have the courtesy of letting the paying customers know.
Investor Village site still down it seems. Has anyone heard anything re. a fix?
Thanks, but I don't think that far down the road with a stock who's PPS is at this level.
To me, these stocks are glorified Pinks.
JMO
They have cash until the end of Q3, but if additional funding isn't in place by then (at the latest) it's lights out. Shareholders should consider voting "against" a number of corporate incentives on the table. Officers should not be receiving bonuses this time around.
Looking like the climb back up, is still on track in the new month.
They have had countless secondaries over the years, but never an approved therapy. This company has been nothing more than a capital consuming beast created by Edward Lanphier, and he as well as others, mainly management taking shareholders to the cleaners, while they live in luxury! https://finance.yahoo.com/news/sangamo-therapeutics-announces-pricing-24-120500032.html
From the 10-K: ''Based on our current operating plan, our cash, cash equivalents and marketable securities as of December 31, 2023 are expected to allow us to meet our liquidity requirements only into the third quarter of 2024. Although we have been actively seeking, and continue to actively seek, substantial additional capital, including through public or private equity or debt financing, royalty financing or other sources, such as strategic collaborations and other direct investments in our programs, we have been unsuccessful in securing any such additional capital to date. As a result, we have explored, and continue to explore, whether filing for bankruptcy protection is in the best interest of our Company and our stakeholders.''
Bought some today. Risk/Reward is definitely worth it here.
It was critical! I hate reverse splits. That's where we were headed if we didn't hold a buck today. BRAVO!
Spreading the word. Buy SGMO. Hitting up Reddit we need them behind us. Cheers.
As I said there won't be any announcement regarding the earnings until after we close tomorrow. It's critical we stay above a dollar for 10 straight days. So tomorrow I expect the shorts to try and drive us below a dollar near the close. I have lots of ammo ready to buy the offer to fight the bastards off! You do the same amigo!
We'll be good when we attain compliance after the close on Thursday. God willing the shorts don't upend that! Then and only then will the fool of a CEO announce the earnings call.
I think early earnings next week maybe Monday. Looking good and feeling good.
Could turn out to be good and go to 5+ somewhat quickly if things develop correctly. Cash burn will be pretty much cut in half this year too
I smell buyout or merger. Here we go. Volume is off the charts. All institutions and backdoor deals.
Followers
|
86
|
Posters
|
|
Posts (Today)
|
1
|
Posts (Total)
|
797
|
Created
|
09/09/04
|
Type
|
Free
|
Moderators |
http://www.sangamo.com/index.php
http://finance.yahoo.com/q/ks?s=SGMO+Key+Statistics
Sangamo Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on translating ground-breaking science into genomic therapies that transform patients' lives using platform technologies in genome editing, gene therapy, gene regulation, and cell therapy. The company?s proprietary zinc finger DNA-binding protein (ZFP) technology enables specific genome editing and gene regulation. The ZFPs could be engineered to make ZFP nucleases (ZFNs), proteins that could be used to specifically modify DNA sequences by adding or knocking out specific genes; and ZFP transcription factors (ZFP TFs), proteins that can be used to turn genes on or off. Its therapeutic products include SB-728-T, a ZFN-mediated autologous T-cell product for human immunodeficiency virus and acquired immunodeficiency syndrome (HIV/AIDS), which is in Phase II and Phase I clinical trials; and SB-728-HSPC that is in Phase I/II clinical trials for HIV/AIDS. The company also engages in Phase I/II studies of in vivo genome editing applications of ZFP Therapeutics for hemophilia B, Hemophilia A, and Mucopolysaccharidosis I (MPS) and MPS II, which are lysosomal storage disorder (LSD); proprietary preclinical programs in other LSDs; and research stage programs in certain central nervous system disorders and cancer immunotherapies. It has collaborative partnerships with Biogen Inc. to develop therapeutic genome editing products in hemoglobinopathies; and with Shire International GmbH to develop the preclinical development program in Huntington?s disease, as well as license agreement with Sigma-Aldrich Corporation to develop ZFP-based laboratory research reagents and Dow AgroSciences, LLC to modify the genomes or alter protein expression of plant cells, plants, or plant cell cultures. The company was formerly known as Sangamo BioSciences, Inc. and changed its name to Sangamo Therapeutics, Inc. in January 2017. Sangamo Therapeutics, Inc. was founded in 1995 and is headquartered in Richmond, California.
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |